Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04300127 · ClinicalTrials.gov registry record · Early Phase 1
Pioglitazone for Idiopathic Gastroparesis
A Early Phase 1 study of Gastroparesis, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT04300127: Completed Early Phase 1 study of Gastroparesis, sponsored by Johns Hopkins University.
NCT04300127 is a Early Phase 1 study of Gastroparesis that has completed, run by Johns Hopkins University. The registered enrollment target is 14 participants, below the 302-participant average among 44 other Gastroparesis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04300127, a Early Phase 1 study of Gastroparesis, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The principal objective of this pilot study will be to evaluate whether 8 weeks of treatment of pioglitazone will improve symptoms as measured by the Gastrointestinal Symptom Index (GCSI) in patients with Idiopathic Gastroparesis.
Primary Outcome
The effect of Pioglitazone on nausea, early satiety, postprandial fullness, and upper abdominal pain as per changes in patient scoring in The American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index (GCSI) which has been designed to assess symptoms associated with gastroparesis. Symptoms are rated as none (0), mild (1), moderate (2), severe (3), very severe (4) scale of the worst severity of the symptom over the last 24 hours. Values reported represent the mean pa
Conditions Studied
Interventions
- DRUG Pioglitazone 30 mg
Study Locations (1)
Maryland
- Johns Hopkins Bayview Medical Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2019-10-24 |
| Est. Completion | 2025-03-18 |
| Phase | Early Phase 1 |
What the finished NCT04300127 record still lists
NCT04300127 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 302-participant average among 44 other Gastroparesis trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Gastroparesis appearing as the primary indexed condition, and to 1 intervention - of which Pioglitazone 30 mg is the first listed.
NCT04300127 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT04300127 about?
NCT04300127 is a clinical study titled "Pioglitazone for Idiopathic Gastroparesis". The principal objective of this pilot study will be to evaluate whether 8 weeks of treatment of pioglitazone will improve symptoms as measured by the Gastrointestinal Symptom Index (GCSI) in patients with Idiopathic Gastroparesis.
What is the current status of trial NCT04300127?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 14 participants. The study started on 2019-10-24. Estimated completion is 2025-03-18.
What conditions does trial NCT04300127 study?
This clinical trial studies the following conditions: Gastroparesis.
What interventions are being tested in trial NCT04300127?
The interventions under investigation include: Pioglitazone 30 mg (DRUG).
Who is sponsoring clinical trial NCT04300127?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04300127 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastroparesis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04300127's enrollment target sits among peer trials
14 39th of 44 higher than 5 of 44 other Gastroparesis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastroparesis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Growth Hormone for the Treatment of Gastroparesis
RECRUITING · Early Phase 1
-
Gastroparesis Registry 4
RECRUITING
-
The Use of Body Surface Gastric Mapping in Assessing the Clinical Success of G-POEM
RECRUITING · NA
-
Study of Gastric Motility in Eosinophilic Gastritis
RECRUITING
-
Indiana University Gastrointestinal Motility Diagnosis Registry
RECRUITING
-
Compassionate Use of Domperidone for Refractory Gastroparesis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy